A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults

References

• WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser 2013:1-139, back cover.
   Web of Science ®Google Scholar
• Yu J, Li H, Tang Q, Rayner S, Han N, Guo Z, Liu H, Adams J, Fang W, Tao X, et al. The spatial and temporal dynamics of rabies in China. PLoS Negl Trop Dis 2012; 6:e1640; PMID:22563518; http://dx.doi.org/10.1371/journal.pntd.0001640
   PubMed Web of Science ®Google Scholar
• Zhang L, Wilson DP. Trends in notifiable infectious diseases in China: implications for surveillance and population health policy. PLoS One 2012; 7:e31076; PMID:22359565; http://dx.doi.org/10.1371/journal.pone.0031076
   PubMed Web of Science ®Google Scholar
• Hu R, Tang Q, Tang J, Fooks AR. Rabies in China: an update. Vector Borne Zoonotic Dis 2009; 9:1-12; PMID:18803503; http://dx.doi.org/10.1089/vbz.2008.0046
   PubMed Web of Science ®Google Scholar
• Si H, Guo ZM, Hao YT, Liu YG, Zhang DM, Rao SQ, Lu JH. Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province. BMC Infect Dis 2008; 8:113; PMID:18717989; http://dx.doi.org/10.1186/1471-2334-8-113
   PubMed Web of Science ®Google Scholar
• Yin CP, Zhou H, Wu H, Shen XX, Wang LH, Yin WW, Wang SM, Tang Q. [Epidemiological analysis of rabies in 2010, China]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2011; 25:434-6; PMID:22734228;
   PubMedGoogle Scholar
• Hemachudha T, Wacharapluesadee S, Mitrabhakdi E, Wilde H, Morimoto K, Lewis RA. Pathophysiology of human paralytic rabies. J Neurovirol 2005; 11:93-100; PMID:15804967; http://dx.doi.org/10.1080/13550280590900409
   PubMed Web of Science ®Google Scholar
• Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 1991; 9:573-6; PMID:1771970; http://dx.doi.org/10.1016/0264-410X(91)90244-Z
   PubMed Web of Science ®Google Scholar
• Colnot F, Sureau P, Alexandre JL, Arnaudo JP, Hesse JY, Jeanmaire H. Post-exposure antirabies vaccination. Early serological response to vaccine cultivated on VERO cells using a reduced 2-1-1 schedule. Presse Med 1994; 23:1609-12; PMID:7831241;
   PubMed Web of Science ®Google Scholar
• Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, Wasi C. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000; 78:693-8; PMID:10859864;
   PubMed Web of Science ®Google Scholar
• Scheiermann N, Baer J, Hilfenhaus J, Marcus I, Zoulek G. Reactogenicity and immunogenicity of the newly developed purified chick embryo cell (PCEC)-rabies vaccine in man. Zentralbl Bakteriol Mikrobiol Hyg A 1987; 265:439-50; PMID:2445127;
   PubMedGoogle Scholar
• Vodopija I, Sureau P, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M, Smerdel S. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 1986; 4:245-8; PMID:3541428; http://dx.doi.org/10.1016/0264-410X(86)90138-6
   PubMed Web of Science ®Google Scholar
• Kamoltham T, Thinyounyong W, Phongchamnaphai P, Phraisuwan P, Khawplod P, Banzhoff A, Malerczyk C. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J Pediatr 2007; 151:173-7; PMID:17643772; http://dx.doi.org/10.1016/j.jpeds.2007.02.044
   PubMed Web of Science ®Google Scholar
• Quiambao BP, Dimaano EM, Ambas C, Davis R, Banzhoff A, Malerczyk C. Reducing the cost of post-exposure rabies prophylaxis: efficacy of 0.1 ml PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005; 23:1709-14; PMID:15705476; http://dx.doi.org/10.1016/j.vaccine.2004.09.027
   PubMed Web of Science ®Google Scholar
• Dobardzic A, Izurieta H, Woo EJ, Iskander J, Shadomy S, Rupprecht C, Ball R, Braun MM. Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine 2007; 25:4244-51; PMID:17382435; http://dx.doi.org/10.1016/j.vaccine.2007.02.075
   PubMed Web of Science ®Google Scholar
• Malerczyk C, Briggs DJ, Dreesen DW, Banzhoff A. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. J Travel Med 2007; 14:63-4; PMID:17241256; http://dx.doi.org/10.1111/j.1708-8305.2006.00097.x
   PubMed Web of Science ®Google Scholar
• WHO Expert Consultation on rabies. World Health Organ Tech Rep Ser 2005; 931:1-88, back cover; PMID:16485446;
   PubMed Web of Science ®Google Scholar
• Ministry of Health, People's Republic of China. Situation of rabies prevention and control in China. http://www.moh.gov.cn, 2009.;
   Google Scholar
• Liu H, Huang G, Tang Q, Li J, Cao S, Fu C, Cao Q, Liu B, Pan H, Wang M. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Hum Vaccin 2011; 7:220-4; PMID:21311216; http://dx.doi.org/10.4161/hv.7.2.14003
   PubMed Web of Science ®Google Scholar
• Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett SM, Levis R, Meltzer MI, Schaffner W, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 2010; 59:1-9; PMID:20300058
   PubMedGoogle Scholar
• Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett S, Levis R, Meltzer MI, Schaffner W, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009; 27:7141-8; PMID:19925944; http://dx.doi.org/10.1016/j.vaccine.2009.09.029
   PubMed Web of Science ®Google Scholar
• Song M, Tang Q, Wang DM, Mo ZJ, Guo SH, Li H, Tao XY, Rupprecht CE, Feng ZJ, Liang GD. Epidemiological investigations of human rabies in China. BMC Infect Dis 2009; 9:210; PMID:20025742; http://dx.doi.org/10.1186/1471-2334-9-210
   PubMed Web of Science ®Google Scholar
• Hampson K, Cleaveland S, Briggs D. Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries. PLoS Negl Trop Dis 2011; 5:e982; PMID:21408121; http://dx.doi.org/10.1371/journal.pntd.0000982
   PubMed Web of Science ®Google Scholar
• Wang CL, Zhang XW, Yu YX. Study on the compliance and economic cost of rabies vaccination. Zhongguo Yi Miao He Mian Yi 2010; 16:254-7; PMID:20726270;
   PubMedGoogle Scholar
• Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, Shaw A, Zinsstag J, Meslin FX. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005; 83:360-8; PMID:15976877;
   PubMed Web of Science ®Google Scholar
• WHO expert committee on rabies. Guide for post-exposure treatment. 8th report. WHO tecnical report 824. Geneva, Switzerland: World Health Organization; 1992
   Google Scholar
• Suwansrinon K, Wilde H, Benjavongkulchai M, Banjongkasaena U, Lertjarutorn S, Boonchang S, Suttisri R, Khowplod P, Daviratanasilpa S, Sitprija V. Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity. Vaccine 2006; 24:3878-80; PMID:16530893; http://dx.doi.org/10.1016/j.vaccine.2006.02.027
   PubMed Web of Science ®Google Scholar
• Zalan E, Wilson C, Pukitis D. A microtest for the quantitation of rabies virus neutralizing antibodies. J Biol Stand 1979; 7:213-20; PMID: 387798
   PubMedGoogle Scholar